Navigation Links
EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
Date:3/25/2008

ROCKVILLE, Md., March 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that James S. Burns, President and Chief Executive Officer, will present a Corporate overview at the BioCentury Future Leaders in the Biotech Industry Conference, to be held at the Millennium Broadway Hotel & Conference Center, March 27, 2008. Mr. Burns' presentation is scheduled for Thursday, March 27, 2008 at 4:00 p.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Mr. Burns' live presentation will be web cast and can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, is in a Phase 1 study in advanced cancer patients, and ENMD-2076, a selective kinase inhibitor, is expected to begin a Phase 1 study in 2Q08. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases,
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. EntreMed Announces 2008 Corporate and Clinical Program Priorities
2. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
3. EntreMed to Present at BIO CEO and Investor Conference
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
6. EntreMed Appoints Senior Vice President of Research and Development
7. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
8. Osteotech to Present at the Sidoti Conference in New York
9. BioMS Medical to present at BioCentury Conference
10. Biodel Inc. to Present at the BioCentury Future Leaders Conference on March 27th, 2008
11. Evotec AG: Fiscal Year 2007 Results Presentation on March 28, 2008 Live on the Internet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... VANCOUVER, Washington , July 30, 2015 ... "Biosimulation Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, ... (Drug Discovery & Development, Preclinical, Clinical Trial), by End ... the Biosimulation Market is expected to reach USD 2,107.99 ... at a CAGR of 15.29%. Browse ...
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
(Date:7/29/2015)... , July 30, 2015 ... reports results for the second quarter of 2015. ... group,s results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics ... Q2 results - Performance drivers ...
(Date:7/29/2015)... - BioAmber Inc. (NYSE: BIOA ) today announced that ... has resigned.  The Company has hired Andrew Ashworth ... December 2014, as full time interim CFO and has ... Andy Ashworth began his employment today, to ... Andy was the Company,s CFO from September 2011 to ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... THE WOODLANDS, Texas, Aug. 19 US Oncology, ... today that in less than two decades it has ... cancer therapies approved by the US Food and Drug ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20100517/DA06089LOGO ) ...
... oxide compounds, and on its own it ... and physically stretch it, and then it takes on ... new Cornell research. ( Nature , Aug. 19, 2010.) ... titanate become both ferroelectric (electrically polarized) and ferromagnetic (exhibiting ...
... MADISON, Wis., Aug. 18 Mirus Bio now offers ... in large pharma and biotech settings. Mirus Bio,s new ... usable protein by maximizing target protein yields through transient ... components designed for high and reproducible protein yield in ...
Cached Biology Technology:US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research 2US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research 3US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research 4Researchers 'stretch' a lackluster material into a possible electronics revolution 2
(Date:7/21/2015)... July 21, 2015 Today, ZTE announced its ... as well as expected revenues in 2015 that relate to sales ... revenue guidance of approximately 2,200 MSEK for 2015. Jörgen ... leading smartphone manufacturer in China and we ... 02 5 for Axon , ...
(Date:7/20/2015)...  Acuity Market Intelligence,s latest research "The Global ... and Privacy" forecasts that between 2014 and 2020 ... downloaded to smart mobile devices by 2.2 billion ... projected to generate more than $67.9 billion in ... period.    "Biometrics is at the ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... Johns Hopkins researchers have identified a rare gene mutation in ... to evidence that abnormal genes play a role in the ... published in the journal Molecular Psychiatry , say that ... domain protein 3 (NPAS3) appear at high risk of developing ...
... particles in our ocean,s surfaces to increase the marine ... excess amount of it in the atmosphere, have been ... study, published today, 22 January, in IOP Publishing,s journal ... dissolving the naturally occurring mineral olivine and calculates how ...
... Johns Hopkins has decoded a system that makes certain types of ... are high levels of a molecule that becomes embedded in viral ... that, when it reads the code, switches from repairing the DNA ... the find in the Jan. 21 early edition of the ...
Cached Biology News:Evidence mounts for role of mutated genes in development of schizophrenia 2Evidence mounts for role of mutated genes in development of schizophrenia 3Researchers analyse 'rock dissolving' method of geoengineering 2Researchers analyse 'rock dissolving' method of geoengineering 3Researchers show how cells' DNA repair machinery can destroy viruses 2Researchers show how cells' DNA repair machinery can destroy viruses 3
... enables complete conversion of unmethylated cytosines ... hours. The highly sensitive method utilizes ... and a spin-column-based purification and desulfonation ... results for all downstream applications. The ...
... Shimadzus GCMS-QP2010s Gas Chromatograph/Mass Spectrometer, ... of the GCMS-QP2010 Plus, offers high ... with an excellent performance-to-cost ratio. Like ... patented constant linear velocity for optimum ...
... enterprise microarray informatics platform for microarray data storage, ... and use it forever without paying ongoing license ... Acuity has all the analysis tools you need ... quality control statistics and normalization, all the way ...
... Pro is the industry standard microarray image ... of imaging and analysis tools, visualizations, automation ... Pro is included with every GenePix scanner, ... third-party scanners and all types of arrays. ...
Biology Products: